

NCIC CLINICAL TRIALS GROUP - GI DISEASE SITE COMMITTEE

COLON & RECTAL DISEASE ORIENTED WORKING GROUPS

AGENDA

OPEN SESSION

Venue: Stevenson Room, Delta Chelsea Hotel

Date: Saturday, May 3rd, 2008

Time: 8:00 am

Chairs: CDOG: Dr. Derek Jonker & Dr. Sharlene Gill

RDOG: Dr. Nancy Baxter

7:30 am **CONTINENTAL BREAKFAST AVAILABLE**

8:00 am **WELCOME AND INTRODUCTION / MEMBERSHIP UPDATE**

Dr. D. Jonker

8:05 am **EMERGING K-RAS AND CETUXIMAB DATA**

Dr. D. Jonker

8:15 am **BRIEF UPDATE OF ACTIVE TRIALS**

Dr. S. Gill

CRC.2 (N0147): A Randomized Phase III Trial of Oxaliplatin Plus 5-FU with or without Cetuximab after Curative Resection for Patients with Stage III Colon Cancer

CRC.3 (E5202): A Randomized Phase III Study Comparing 5FU Leucovorin and Oxaliplatin versus 5FU Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

CRC.4 (ECOG 5204): Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation.

CRC.5 (CALGB 80405): A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5FU / Leucovorin with Bevacizumab, or Cetuximab, or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

CO.20: A Phase III Randomizes Study of Brivanib Alaninate (BMS-582664) in Combination with Cetuximab (Erbix[®]) versus Placebo in Combination with Cetuximab (Erbix[®]) in Patients Previously Treated with Combination Chemotherapy for Metastatic Colorectal Carcinoma

IND.171: Phase I Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination with Standard Chemotherapy in Patients with Advanced Incurable NSCLC or CRC

IND.187: A Phase I Study Of AZD2281 In Combination With Irinotecan In Patients With Locally Advanced or Metastatic Incurable Colorectal Cancer

8:30 am **INTERGROUP UPDATES**

Colon Cancer

Dr. D. Jonker/Dr. S. Gill

SWOG S0600 iBET (Intergroup Bevacizumab Continuation Trial):

FOLFIRI/irinotecan plus cetuximab versus FOLFIRIR/irinotecan plus cetuximab and bevacizumab in patient with MCRC who have failed first-line oxaliplatin plus bevacizumab.

Rectal Cancer

Dr. N. Baxter

8:50 am **UPDATE OF TRIALS IN DEVELOPMENT****CO.21:** A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients with Early Stage Colon Cancer: A Randomized Controlled Trial (CHALLENGE)

Dr. C. Booth

9:05 am **OTHER**

Clarification of DFS definition for NCIC CTG adjuvant colon studies

Dr. C. Booth

9:15 am **NEW TRIAL PROPOSALS / CONCEPTS FOR DEVELOPMENT**

RFA versus SBRT for unresectable liver mets < 4 cm from colorectal ca

Dr. L. Dawson

Phase II Trial of Induction Irinotecan, Capecitabine and Oxaliplatin (IXO) for Advanced / Recurrent Rectal Cancer

Dr. D. Jonker

9:45 am **CLOSING REMARKS & ADJOURNMENT**

Dr. D. Jonker